Global Graft Versus Host Disease Gvhd Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
4.07 Billion
USD
5.81 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 4.07 Billion |
 시장 규모(예측 연도) |
USD 5.81 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
글로벌 이식편대숙주병(GvHD) 치료 시장, 치료(약물 및 요법), 유형(만성 GvHD, 급성 GvHD 및 예방), 성별(여성 및 남성), 연령(성인 및 소아), 투여 방법(경구, 정맥 주사, 국소 및 기타), 최종 사용자(병원, 이식 센터, 연구소 및 전문 센터), 유통 채널(직접 입찰, 소매 판매 및 기타 - 업계 동향 및 2031년까지의 예측.
이식편대숙주병(GvHD) 치료 시장 분석 및 통찰력
2023년 8월 미국 국립보건원(NIH)에서 발표한 논문에 따르면, 북미, 유럽, 아시아의 24개 HCT 센터에서 실시한 연구에 따르면 GvHD의 자연적 진행을 조사한 결과, 치료가 필요한 급성 GvHD의 총 발생률은 40.9%, 고전적 급성 GvHD의 경우 35.2%, 후기 급성 GvHD의 경우 5.7%였습니다. 고전적 및 후기 급성 GvHD 환자 중 각각 77.8%(1601명 중 1245명)와 75.4%(256명 중 193명)가 전신적 GvHD 치료를 받았습니다. 미국 국립의학도서관에서 발표한 논문에 따르면, 인간 백혈구 항원(HLA)이 일치하는 형제로부터 조혈모세포 이식(HCT)을 받는 환자의 약 절반에게 급성 이식편대숙주병(GvHD)이 발생할 수 있습니다.
Data Bridge Market Research에 따르면 글로벌 이식편대숙주병(GvHD) 치료 시장 규모는 2023년 39억 4,000만 달러에서 2031년 55억 달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 4.4%로 성장할 것으로 예상됩니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
수익 (USD) 10억 |
|
다루는 세그먼트 |
치료(약물 및 요법), 유형(만성 GvHD, 급성 GvHD 및 예방), 성별(여성 및 남성), 연령(성인 및 소아), 투여 방법(경구, 정맥 주사, 국소 및 기타), 최종 사용자(병원, 이식 센터, 연구소 및 전문 센터), 유통 채널(직접 입찰, 소매 판매 및 기타) |
|
적용 국가 |
미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 영국, 스페인, 벨기에, 러시아, 스위스, 덴마크, 유럽 기타 지역, 중국, 일본, 호주, 한국, 인도, 말레이시아, 싱가포르, 필리핀, 인도네시아, 아시아 태평양 기타 지역, 브라질, 아르헨티나, 남미 기타 지역, 남아프리카, 사우디 아라비아, UAE, 쿠웨이트, 바레인, 중동 및 아프리카 기타 지역 |
|
시장 참여자 포함 |
Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd., Astellas Pharma Inc. 등 |
시장 정의
이식편대숙주병(GvHD)은 줄기세포 또는 골수 이식 후 발생할 수 있는 질환으로, 새로 이식된 기증자 세포가 이식 수혜자의 신체를 공격합니다. 이 면역 반응은 경미한 것부터 심각한 것까지 다양한 증상과 합병증을 일으킬 수 있습니다. GvHD는 이식 의학에서 중요한 문제이며 신중한 관리가 필요합니다.
이식편대숙주병(GvHD) 치료는 GvHD의 증상을 관리하고 완화하는 데 사용되는 다양한 의학적 개입을 말합니다. 이러한 치료는 수혜자의 조직과 장기에 대한 기증자 세포의 면역 반응을 억제하는 것을 목표로 합니다. GvHD에 대한 일반적인 치료에는 코르티코스테로이드와 같은 면역 억제 약물과 면역 반응의 특정 측면을 표적으로 삼는 다른 약물이 포함됩니다. 심각한 경우 광교환 또는 기타 면역 조절 요법과 같은 보다 집중적인 요법을 사용할 수 있습니다. 치료 선택은 GvHD의 심각도와 개별 환자에 특정한 다른 요인에 따라 달라집니다.
글로벌 이식편대숙주병(GvHD) 치료 시장 역학
이 섹션에서는 시장 동인, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전사
- 조혈모세포 이식(HSCT)의 증가
조혈모세포 이식(HSCT)의 증가는 이식편대숙주병(GvHD) 치료에 대한 수요를 크게 증가시키는 요인입니다. 이러한 추세는 주로 백혈병, 림프종, 골수종과 같은 혈액암의 유병률이 증가함에 따라 촉진되며, 이러한 암은 종종 치료 옵션으로 HSCT를 필요로 합니다. 또한, 무형성 빈혈 및 특정 유전적 질환과 같은 다른 혈액학적 장애도 질병 관리를 위해 HSCT를 필요로 합니다.
HSCT를 받는 환자 수가 계속 증가함에 따라 효과적인 GvHD 치료에 대한 수요도 증가하고 있습니다. GvHD는 HSCT의 일반적인 합병증으로, 이식된 기증자 세포가 수혜자의 조직을 공격하여 잠재적으로 심각하고 생명을 위협하는 증상을 유발할 때 발생합니다. 따라서 HSCT의 증가는 이 합병증의 영향을 관리하고 완화하기 위한 GvHD 치료의 필요성이 높아짐을 직접적으로 의미합니다.
제지
- 높은 약물 비용과 지지 치료
이식편대숙주병(GvHD)을 치료하는 데 드는 높은 비용은 약물의 단순한 비용 부담을 넘어서는 제약을 가합니다. 여기에는 약물, 입원, 외래 방문, 진단 검사 및 지지 요법을 포함한 종합적 치료와 관련된 비용이 포함됩니다. 의료 자원과 재정적 제약이 제한된 개발 지역에서 이러한 비용은 특히 부담스러울 수 있으며, 종종 지연되거나 부적절한 치료로 이어질 수 있습니다.
타크로리무스 및 사이클로스포린과 같은 칼시뉴린 억제제는 GvHD 치료의 중요한 구성 요소이지만, 높은 가격으로 인해 의료 예산에 부담을 줄 수 있습니다. 메토트렉세이트 및 미코페놀레이트 모페틸과 같은 항대사제, 룩솔리티닙, 벨루모수딜 및 이브루티닙과 같은 면역 억제제, 메틸프레드니솔론 및 프레드니솔론을 포함한 코르티코스테로이드도 필수적이지만 환자에게 과도한 경제적 부담을 줍니다.
기회
- 전략적 이니셔티브와 파트너십을 통한 시장 확장
전략적 협업을 통한 시장 확대는 GvHD(이식편대숙주병) 치료 시장에서 활동하는 기업에 매우 효과적인 접근 방식이 될 수 있습니다. GvHD에 대한 혁신적인 치료법과 포괄적인 치료 솔루션에 대한 수요가 계속 증가함에 따라 기업은 전략적 파트너십과 협업을 활용하여 시장 입지를 확대하고 변화하는 환자 요구에 맞게 조정된 다양한 제품 포트폴리오를 제공할 수 있습니다. 연구 기관, 학술 센터 및 생명공학 기업과 협력함으로써 GvHD 시장 참여자는 최첨단 기술, 새로운 치료적 접근 방식 및 과학적 전문 지식을 활용하여 제품 개발 노력을 진전시킬 수 있습니다. 이러한 협업을 통해 기업은 개인화된 세포 치료, 표적 생물학적 제제 및 지지적 치료 개입을 포함하여 유망한 GvHD 치료법의 발견 및 개발을 가속화할 수 있습니다. 또한 주요 의견 리더 및 환자 옹호 단체와의 전략적 제휴는 시장 접근을 용이하게 하고 신뢰, 신뢰성 및 환자 참여를 촉진하여 새로운 치료법의 채택을 강화합니다.
또한 전략적 이니셔티브를 통한 시장 확장을 통해 GvHD 시장 참여자는 제품 포트폴리오를 다양화하고 GvHD 시장에서 더 큰 점유율을 확보할 수 있습니다. 회사는 전문성과 리소스를 활용하여 보완적인 제품과 서비스를 개발함으로써 질병 연속체의 여러 단계에 걸쳐 GvHD 환자의 다면적인 요구를 해결하는 포괄적인 케어 솔루션을 제공할 수 있습니다.
도전
- GvHD 치료에 대한 엄격한 규정
엄격한 규제는 앞으로 GvHD 시장에 상당한 과제를 안겨줍니다. 이 분야가 새로운 치료법과 치료 양식의 개발로 계속 발전함에 따라 규제 당국은 안전성, 효능 및 품질 관리에 대한 엄격한 기준을 부과합니다. 이러한 규제 요건을 충족하려면 임상 전 및 임상 개발에 상당한 투자가 필요하며, 규제 승인을 위한 광범위한 문서화 및 데이터 제출이 필요합니다. 또한 GvHD의 복잡성, 이질적인 표현 및 표준화된 진단 기준의 부족은 규제 평가 및 승인 프로세스를 더욱 복잡하게 만듭니다. 규제 기관은 종종 새로운 치료법의 효능뿐만 아니라 기존 치료법에 대한 비교 효과를 입증하는 강력한 임상 시험 데이터를 요구합니다. 이를 위해 장기간의 추적 기간이 있는 대규모의 잘 설계된 임상 시험이 필요하며, 이는 제품 개발에 대한 타임라인이 길어지고 비용이 증가합니다.
최근 개발 사항
- 2024년 3월, 존슨앤존슨은 Ambrx Biopharma, Inc. 인수를 성공적으로 완료했다고 발표했습니다. 이 임상 단계의 바이오제약 회사는 차세대 항체 약물 접합체(ADC)를 설계하고 개발하는 데 사용되는 독점적인 합성 생물학 기술 플랫폼을 보유하고 있습니다. 이 인수는 존슨앤존슨에게 표적 종양학 치료법을 만들고, 개발하고, 마케팅할 수 있는 독특한 기회를 제공합니다.
- 2024년 2월, AbbVie Inc.와 Tentarix Biotherapeutics는 종양학 및 면역학 분야에서 조건부 활성, 다중 특이적 생물학을 공동으로 발견하고 개발하기 위한 파트너십을 발표했습니다. 이 협력은 Tentarix의 독점적 Tentacles™ 플랫폼과 함께 이러한 분야에서 AbbVie의 광범위한 경험을 활용할 것입니다. 2023년 4월, Medtronic과 DaVita Inc.는 신장 건강을 혁신하고 환자 중심 기술 솔루션을 발전시키는 데 전념하는 독립 회사인 Mozarc Medical을 공동으로 시작했습니다.
- 2024년 2월, Novartis AG는 혁신적인 종양학 의약품에 중점을 둔 독일 바이오제약 회사인 MorphoSys AG를 인수하기로 합의했습니다. 이 인수는 표준 마감 조건 및 규제 승인에 따라 Novartis의 종양학 파이프라인을 강화하고 혈액학 분야에서 글로벌 입지를 확대합니다.
- 2022년 5월, Bristol-Myers Squibb Company는 일본 보건복지부에서 GvHD 성인 환자의 1차 치료제로 Opdivo와 Yervoy의 조합을 승인했다고 발표했습니다. 이를 통해 회사는 제품 포트폴리오를 강화할 수 있습니다.
- 2020년 1월, Astellas Pharma Inc.는 Adaptimmune과 암 치료를 위한 줄기세포 유래 allogenc CAR-T 및 TCR T-Cell Therapies를 개발하기 위한 계약을 체결했다고 발표했습니다. 이를 통해 회사는 향후 몇 년 동안 시장을 더욱 확보하는 데 도움이 될 것입니다.
글로벌 이식편대숙주병(GvHD) 치료 시장 범위
글로벌 이식편대숙주병(GvHD) 치료 시장은 치료, 유형, 성별, 연령, 투여 방법, 최종 사용자 및 유통 채널을 기준으로 7개의 주요 세그먼트로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
치료
- 약물
- 요법
치료 방법을 기준으로 시장은 약물 치료와 치료법으로 구분됩니다.
유형
- 만성 GvHD
- 급성 GvHD
- 예방적
시장은 유형을 기준으로 만성 GvHD, 급성 GvHD, 예방적 GvHD로 구분됩니다.
성별
- 여성
- 남성
성별을 기준으로 시장은 여성과 남성으로 구분됩니다.
나이
- 성인
- 소아과
연령을 기준으로 시장은 성인과 소아로 구분됩니다.
투여방법
- 경구
- 정맥
- 뉴스 영화
- 기타
투여 방법을 기준으로 시장은 경구, 정맥 주사, 국소 및 기타로 구분됩니다.
최종 사용자
- 병원
- 이식 센터
- 제요
- 전문 센터
최종 사용자를 기준으로 시장은 병원, 이식 센터, 연구소, 전문 센터로 구분됩니다.
유통 채널
- 직접 입찰
- 소매 판매
- 기타
유통 채널을 기준으로 시장은 직접 입찰, 소매 판매 및 기타로 세분화됩니다.
글로벌 이식편대숙주병(GvHD) 치료 시장 지역 분석/통찰력
글로벌 이식편대숙주병(GvHD) 치료 시장은 치료, 유형, 성별, 연령, 투여 방법, 최종 사용자 및 유통 채널을 기준으로 7개의 주요 세그먼트로 구분됩니다.
이 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 영국, 스페인, 벨기에, 러시아, 스위스, 덴마크, 유럽의 다른 지역, 중국, 일본, 호주, 한국, 인도, 말레이시아, 싱가포르, 필리핀, 인도네시아, 아시아 태평양의 다른 지역, 브라질, 아르헨티나, 남미의 다른 지역, 남아프리카, 사우디 아라비아, UAE, 쿠웨이트, 바레인, 그리고 중동과 아프리카의 다른 지역입니다.
북미 지역은 첨단 의료 인프라, 높은 조혈 세포 이식률, 연구 개발에 대한 강력한 투자, 지원적인 규제 환경, 상당한 의료 지출, 더 큰 질병 인식으로 인해 시장을 지배할 것으로 예상됩니다. 이러한 요인은 새로운 GvHD 치료법의 개발 및 채택에서 이 지역의 선도적 위치에 기여합니다. 미국은 조혈 줄기 세포 이식(HSCT)의 증가로 인해 북미에서 우위를 점할 것으로 예상됩니다. 일본은 아시아 태평양 지역에서 첨단 의료 기술, 의료 연구 개발에 대한 상당한 투자, 높은 조혈 세포 이식률, 새로운 치료법 승인에 대한 강력한 정부 지원 및 규제 효율성, GvHD에 대한 대중 인식 및 교육 증가로 인해 우위를 점할 것으로 예상됩니다. 독일은 첨단 기술 채택, 강력한 의료 인프라, 성숙한 시장으로 인해 유럽 지역에서 우위를 점할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제와 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 글로벌 이식편대숙주병(GvHD) 치료 시장 점유율 분석
글로벌 이식편대숙주병(GvHD) 치료 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 적용 우세, 제품 유형 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.
시장에서 활동하는 주요 기업으로는 Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd., Astellas Pharma Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT)
6.1.2 RISING AWARENESS CAMPAIGNS AND PATIENT EDUCATION
6.1.3 ADVANCEMENTS IN TREATMENT OPTIONS FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE
6.2.2 DISEASE HETEROGENEITY IN GRAFT-VERSUS-HOST DISEASE (GVHD) IMPLICATIONS FOR TREATMENT AND CLINICAL TRIALS
6.3 OPPORTUNITIES
6.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP
6.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT
6.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES
6.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT
7 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY TYPE
7.1 OVERVIEW
7.2 CHRONIC GVHD
7.2.1 CORTICOSTEROIDS
7.2.1.1 PREDNISOLONE
7.2.1.2 METHYLPREDNISOLONE
7.2.2 IMMUNOSUPPRESSIVE
7.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.2.2.2 METHOTREXATE (MTX)
7.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
7.2.2.4 OTHERS
7.2.3 CALCINEURIN INHIBITORS
7.2.4 OTHERS
7.2.5 BRANDED
7.2.5.1 REZUROCK
7.2.5.2 IMBRUVICA
7.2.5.3 JAKAFI
7.2.6 GENERIC
7.3 ACUTE GVHD
7.3.1 CORTICOSTEROIDS
7.3.1.1 METHYLPREDNISOLONE
7.3.1.2 PREDNISOLONE
7.3.2 IMMUNOSUPPRESSIVE
7.3.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.3.2.2 RUXOLITINIB
7.3.2.3 OTHERS
7.3.3 CALCINEURIN INHIBITORS
7.3.3.1 TACROLIMUS (TAC)
7.3.3.2 CYCLOSPORIN (CSA)
7.3.4 OTHERS
7.4 PROPHYLACTIC
7.4.1 CYCLOSPORIN (CSA)
7.4.2 METHOTREXATE (MTX)
7.4.3 TACROLIMUS (TAC)
7.4.4 METHYLPREDNISOLONE
7.4.5 OTHERS
7.4.6 GENERIC
7.4.7 BRANDED
8 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY AGE
8.1 OVERVIEW
8.2 ADULTS
8.3 PEDIATRIC
9 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 FEMALE
9.3 MALE
10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INTRAVENOUS
10.4 TOPICAL
10.5 OTHERS
11 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CORTICOSTEROIDS
11.2.1.1 METHYLPREDNISOLONE
11.2.1.2 PREDNISOLONE
11.2.2 IMMUNOSUPPRESSIVE
11.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
11.2.2.2 METHOTREXATE (MTX)
11.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
11.2.2.4 OTHERS
11.2.3 CALCINEURIN INHIBITORS
11.2.3.1 TACROLIMUS (TAC)
11.2.3.2 CYCLOSPORIN (CSA)
11.2.3.3 OTHERS
11.2.4 BRANDED
11.2.4.1 REZUROCK
11.2.4.2 IMBRUVICA
11.2.4.3 JAKAFI
11.2.4.4 ORENCIA
11.2.4.5 OTHERS
11.2.5 GENERIC
11.3 THERAPY
12 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 TRANSPLANT CENTERS
12.4 INSTITUTES
12.5 SPECIALITY CENTERS
13 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 FRANCE
14.3.3 ITALY
14.3.4 U.K.
14.3.5 SPAIN
14.3.6 BELGIUM
14.3.7 RUSSIA
14.3.8 SWITZERLAND
14.3.9 DENMARK
14.3.10 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 JAPAN
14.4.2 CHINA
14.4.3 AUSTRALIA
14.4.4 SOUTH KOREA
14.4.5 INDIA
14.4.6 MALAYSIA
14.4.7 SINGAPORE
14.4.8 PHILIPPINES
14.4.9 INDONESIA
14.4.10 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SOUTH AFRICA
14.6.2 SAUDI ARABIA
14.6.3 U.A.E.
14.6.4 KUWAIT
14.6.5 BAHRAIN
14.6.6 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 BRISTOL-MYERS SQUIBB COMPANY
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ABBVIE INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 JANSSEN GLOBAL SERVICES, LLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS/NEWS
17.5 INCYTE
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ALKEM LABORATORIES LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ASTELLAS PHARMA INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 MALLINCKRODT
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS/NEWS
17.9 NOVARTIS AG
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL ADULTS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL FEMALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 20218-2032 (USD THOUSAND)
TABLE 21 GLOBAL MALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL ORAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL OTHERS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 39 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 GLOBAL SPECIALTY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 75 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 76 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 77 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 78 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 79 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 80 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 103 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 104 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 105 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 106 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 107 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 111 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 119 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 129 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 130 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 131 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 132 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 133 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 134 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 138 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 139 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 140 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 146 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 147 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 165 METHYLPREDNISOLONE
TABLE 166 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 170 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 171 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 172 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 173 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 174 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 176 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 177 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 178 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 179 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 181 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 191 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 192 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 193 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 196 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 197 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 198 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 199 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 200 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 202 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 203 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 204 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 205 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 207 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 208 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 209 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 210 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 211 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 212 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 213 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 217 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 218 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 219 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 223 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 224 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 225 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 226 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 228 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 229 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 230 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 231 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 232 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 233 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 234 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 235 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 236 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 237 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 238 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 239 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 243 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 244 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 245 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 248 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 249 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 250 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 251 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 252 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 254 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 255 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 256 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 257 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 258 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 259 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 260 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 261 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 262 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 263 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 264 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 265 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 271 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 274 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 275 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 276 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 277 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 278 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 280 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 281 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 282 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 283 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 284 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 285 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 286 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 287 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 288 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 289 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 290 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 291 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 295 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 296 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 297 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 300 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 301 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 302 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 303 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 304 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 306 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 307 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 308 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 310 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 311 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 312 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 313 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 314 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 315 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 316 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 317 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 321 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 322 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 323 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 326 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 327 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 328 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 329 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 330 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 332 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 333 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 334 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 335 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 336 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 337 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 338 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 339 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 340 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 341 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 342 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 343 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 347 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 348 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 349 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 352 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 353 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 354 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 355 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 356 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 358 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 359 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 360 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 361 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 362 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 363 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 364 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 365 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 366 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 367 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 368 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 369 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 371 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 373 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 374 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 375 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 378 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 379 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 380 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 381 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 382 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 384 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 385 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 386 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 387 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 388 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 389 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 390 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 391 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 392 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 393 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 394 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 395 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 399 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 400 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 401 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 405 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 407 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 408 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 410 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 411 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 412 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 413 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 414 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 415 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 416 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 417 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 418 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 419 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 420 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 421 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 422 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 423 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 427 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 428 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 429 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 432 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 433 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 434 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 435 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 436 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 439 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 440 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 441 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 442 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 443 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 444 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 445 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 446 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 447 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 448 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 449 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 453 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 454 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 455 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 458 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 459 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 460 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 461 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 462 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 464 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 466 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 467 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 468 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 469 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 470 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 471 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 472 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 473 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 474 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 475 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 479 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 480 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 481 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 484 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 485 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 486 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 487 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 488 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 490 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 491 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 493 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 494 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 495 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 496 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 497 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 498 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 499 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 500 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 501 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 505 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 506 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 507 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 510 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 511 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 512 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 513 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 514 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 516 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 517 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 518 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 519 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 520 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 521 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 522 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 523 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 524 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 525 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 526 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 527 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 531 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 532 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 533 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 536 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 537 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 538 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 539 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 540 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 542 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 543 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 544 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 545 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 547 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 548 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 549 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 550 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 551 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 552 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 553 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 557 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 558 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 559 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 562 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 563 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 564 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 565 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 566 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 568 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 569 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 570 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 571 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 572 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 573 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 574 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 575 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 576 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 577 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 578 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 579 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 580 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 581 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 583 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 584 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 585 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 588 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 589 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 590 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 591 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 592 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 594 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 595 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 596 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 597 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 598 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 599 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 600 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 601 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 602 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 603 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 604 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 605 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 609 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 610 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 611 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 614 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 615 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 616 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 617 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 618 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 621 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 622 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 623 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 624 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 625 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 626 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 627 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 628 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 629 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 630 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 631 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 635 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 636 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 637 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 640 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 641 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 642 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 643 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 644 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 646 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 648 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 650 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 651 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 652 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 653 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 654 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 655 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 656 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 657 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 661 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 662 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 663 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 666 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 667 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 668 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 669 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 670 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 672 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 673 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 675 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 676 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 677 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 678 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 679 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 680 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 681 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 682 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 683 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 684 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 685 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 689 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 690 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 691 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 694 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 695 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 696 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 697 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 698 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 700 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 701 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 702 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 703 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 704 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 705 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 706 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 707 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 708 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 709 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 710 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 711 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 715 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 716 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 717 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 718 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 720 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 721 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 722 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 723 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 724 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 726 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 727 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 728 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 729 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 730 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 731 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 732 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 733 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 734 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 735 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 736 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 737 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 741 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 742 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 743 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 746 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 747 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 748 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 749 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 750 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 752 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 753 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 754 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 755 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 756 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 757 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 758 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 759 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 760 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 761 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 762 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 763 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 764 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 765 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 768 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 769 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 770 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 771 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 774 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 775 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 776 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 777 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 778 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 779 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 780 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 781 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 782 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 783 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 784 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 785 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 787 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 788 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 789 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 790 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 791 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 795 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 796 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 797 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 800 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 801 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 802 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 803 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 804 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 805 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 806 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 807 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 808 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 809 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 810 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 811 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 812 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 813 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 814 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 815 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 816 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 817 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 821 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 822 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 823 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 824 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 825 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 826 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 827 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 828 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 829 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 830 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 832 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 833 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 834 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 835 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 836 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 837 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 838 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 839 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 840 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 841 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 842 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 843 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 846 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 847 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 848 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 849 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 850 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 851 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 852 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 853 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 854 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 855 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 856 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 857 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 858 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 859 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 860 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 861 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 862 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 863 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 864 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 865 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 866 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 867 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 868 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 869 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 870 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 871 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 872 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 873 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 874 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 875 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 878 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 879 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 880 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 881 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 882 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 884 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 885 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 886 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 887 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 888 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 889 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 890 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 891 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 892 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 893 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 894 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 895 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 896 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 897 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 899 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 900 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 901 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 904 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 905 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 906 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 907 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 908 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 910 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 911 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 912 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 913 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 914 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 915 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 916 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE GROWING NUMBER OF STEM CELL TRANSPLANTATIONS IS DRIVING THE GROWTH OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN 2025 AND 2032
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING REGION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 16 STRATEGIC DECISIONS
FIGURE 17 TWO SEGMENTS COMPRISE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
FIGURE 19 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2024
FIGURE 20 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 21 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 22 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2024
FIGURE 24 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2025-2032 (USD THOUSAND)
FIGURE 25 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, CAGR (2025-2032)
FIGURE 26 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 27 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2024
FIGURE 28 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 29 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 30 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2024
FIGURE 32 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 33 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 38 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 39 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER 2024
FIGURE 40 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 41 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, CAGR (2025-2032)
FIGURE 42 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, LIFELINE CURVE
FIGURE 43 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 44 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 45 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 46 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 48 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 49 NORTH AMERICA GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 50 EUROPE GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 51 AISA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
